These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Xu D; Li N; He Y; Timofeyev V; Lu L; Tsai HJ; Kim IH; Tuteja D; Mateo RK; Singapuri A; Davis BB; Low R; Hammock BD; Chiamvimonvat N Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18733-8. PubMed ID: 17130447 [TBL] [Abstract][Full Text] [Related]
8. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Duflot T; Roche C; Lamoureux F; Guerrot D; Bellien J Expert Opin Drug Discov; 2014 Mar; 9(3):229-43. PubMed ID: 24490654 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling. Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276 [TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase inhibitors and heart failure. Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684 [TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosatrienoic acid pathway in human health and diseases. Bellien J; Joannides R J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468 [TBL] [Abstract][Full Text] [Related]
12. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749 [TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921 [TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. Li N; Liu JY; Timofeyev V; Qiu H; Hwang SH; Tuteja D; Lu L; Yang J; Mochida H; Low R; Hammock BD; Chiamvimonvat N J Mol Cell Cardiol; 2009 Dec; 47(6):835-45. PubMed ID: 19716829 [TBL] [Abstract][Full Text] [Related]
15. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors. Pillarisetti S; Khanna I Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237 [TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase: A potential target for metabolic diseases. He J; Wang C; Zhu Y; Ai D J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325 [TBL] [Abstract][Full Text] [Related]
17. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Elmarakby AA Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511 [TBL] [Abstract][Full Text] [Related]
18. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Xu X; Zhang XA; Wang DW Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627 [TBL] [Abstract][Full Text] [Related]
19. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314 [TBL] [Abstract][Full Text] [Related]
20. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]